Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
15.62
-0.30 (-1.88%)
At close: Apr 28, 2026, 4:00 PM EDT
15.63
+0.01 (0.06%)
After-hours: Apr 28, 2026, 5:53 PM EDT
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Corvus Pharmaceuticals stock have an average target of 30.17, with a low estimate of 11 and a high estimate of 42. The average target predicts an increase of 93.15% from the current stock price of 15.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +156.08% | Apr 17, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $32 → $33 | Buy | Reiterates | $32 → $33 | +111.27% | Mar 13, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $13 → $42 | Strong Buy | Maintains | $13 → $42 | +168.89% | Jan 22, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $32 | Buy | Maintains | $15 → $32 | +104.87% | Jan 21, 2026 |
| Barclays | Barclays | Buy Maintains $16 → $28 | Buy | Maintains | $16 → $28 | +79.26% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
10.83M
EPS This Year
-0.71
from -0.53
EPS Next Year
-0.79
from -0.71
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 20.3M | ||||||
| Avg | n/a | 10.8M | ||||||
| Low | n/a | 2.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.49 | -0.55 | ||||||
| Avg | -0.71 | -0.79 | ||||||
| Low | -1.00 | -1.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.